Ageing and older people who use illicit opioids, cocaine or methamphetamine: a scoping review and literature map

Changing age profile and incidence of injecting drug use initiation among people in Australia who inject drugs: evidence from two national repeated cross-sectional studies

Background

The age of people who inject drugs appears to be increasing in some high-income countries. We aimed to explore trends in the age of people injecting and recently starting to inject drugs in Australia, and to model incidence of initiation over time.

Methods

We obtained data from the Illicit Drug Reporting System (IDRS) and the Australian Needle Syringe Program Survey (ANSPS), which comprise annual cross-sectional surveys with people who inject drugs (2000-2019). Outcome measures were current age, age of initiation, and time since initiation (both surveys), and drug first injected (IDRS only). We estimated time trends in age using quantile regression. We used the relative number of people initiating injecting drug use each year and existing population size estimates to model incidence of initiation.

Findings

In total, 58,465 interviews with people who reported injecting drugs in the past month (33.7% women) were included. In both surveys, the median age increased over the study period (IDRS: 28-43 years; ANSPS 28-44 years). The median time since initiation also increased over the study period (IDRS: 8-22.5 years; ANSPS: 9-24 years), and the median age of initiation increased with calendar year of initiation (IDRS: 18-34 years; ANSPS: 20-30 years). Women tended to be younger and commence injecting drug use at a younger age than men. Modelling suggested that similar numbers of people injected drugs for the first time each year from 1980 (national estimates of 15,570 and 17,020 new initiates using IDRS and ANSPS data, respectively) to 1996 (IDRS: 16,360; ANSPS: 22,300 new initiates), followed by a decisive decline in incidence until 2012 (IDRS: 1110; ANSPS: 1830), whereafter it has fluctuated but remained low. Meth/amphetamine was consistently the predominant drug injected at initiation among IDRS participants, although there were peaks in heroin as the drug injected at initiation in the early 1980s and mid-1990s.

Interpretation

In 2019, most people who were injecting drugs in Australia were part of a cohort that began injecting in the 1980s or 1990s. Consequently, the population was older and had been injecting drugs for longer compared to those injecting drugs in 2000. This has implications for health service delivery to people who inject drugs, with increasing age likely to be accompanied by a rise in chronic health conditions and an increase in injecting duration potentially resulting in higher incidence of injecting-related injuries and diseases.

Funding

Australian Government Department of Health and Aged Care.

A scoping review of harm reduction practices and possibilities among indigenous populations in Australia, Canada, and the United States

BACKGROUND

There is a great diversity of traditions, practices, and experiences among the Indigenous Peoples of North America and Oceania. However, Indigenous Peoples across these regions are affected by the historical and ongoing violence of settler colonialism, resulting in disproportionately heightened drug-related harms. 'Harm reduction' refers to both an ethos and a set of strategies intended to lessen negative social and/or health effects associated with drug use. While harm reduction could therefore be valuable to Indigenous people who use drugs, important concerns remain regarding the culturally specific implementation and outcomes of such strategies. A clearer picture of research regarding harm reduction in Indigenous communities is needed.

METHOD

We conducted a scoping review of primary studies regarding drug use harm reduction approaches among Indigenous communities in Australia, Canada, New Zealand, and the United States. We included studies that (1) reported on harm reduction principles or strategies; and (2) either reported disaggregated results for Indigenous participants or were based on a sample in which at least half of the participants identified as Indigenous. Medline and PsycINFO were searched in March 2024; screening by two independent reviewers was completed in April 2024.

FINDINGS

Screening 578 references generated a corpus of 28 studies, 16 (57 %) of which were conducted in Canada. Indigenous people who use drugs generally reported favourable attitudes towards harm reduction initiatives; other community members and healthcare providers were more hesitant. A variety of harm reduction strategies were discussed, most commonly needle-syringe programs (n = 8, 29 %). Barriers included the availability and acceptability of harm reduction services. Community members expressed concerns regarding cultural appropriateness, but also offered possibilities for improved integration of harm reduction into Indigenous traditions and practices.

INTERPRETATION

This review indicated an emerging, wide-ranging, and somewhat disparate body of literature. While barriers remain, there are promising possibilities for reconceptualizing harm reduction from an Indigenous ethos.

Quality of life whilst ageing in opioid agonist treatment: a narrative analysis

BACKGROUND

Norway has an increasing number of ageing opioid agonist treatment (OAT) patients, with 44% of the 8200 Norwegian OAT patients over 50 in 2023.

METHODS

This study examines the narratives of ageing OAT patients through semi-structured interviews with twelve patients who had been in OAT for 10-20+ years. We used narrative analysis to understand what they experience as important in enhancing or diminishing their quality of life as they age.

RESULTS

Positive relationships, treatment, and stable housing were narrated as enhancing quality of life, while loneliness and isolation, memory problems, comorbidities, and victimization were narrated as diminishing it.

CONCLUSION

Patients experience OAT as both lifesaving as well as potentially limiting their life-quality, illustrating the inbuilt dilemmas of OAT. The study suggests an age-informed treatment model and identifies three thematic implications for practice and further research (on memory issues, victimisation and network-building).

Individuals 45 Years and Older in Opioid Agonist Treatment: A Scoping Review

This scoping review explores the unique challenges and needs faced by ageing individuals, aged 45 and above, in opioid agonist treatment (OAT), noting the earlier onset of age-related impairments among this population. The literature search was conducted in PsycINFO, EMBASE, MEDLINE, CINAHL, and Web of Science. A total of 28 observational studies were included. Five topics were identified: health, treatment, substance use, demographic, and social aspects. Findings reveal that, while health and age-related concerns are often discussed in the literature, limited attention has been given to gender differences, social factors such as financial issues, and psychological factors, which are also critical aspects of the lives of ageing individuals undergoing OAT. This review emphasizes the importance of expanding research to address these gaps, ultimately aiming to improve their overall well-being.

Health disparities and injection drug use behaviors among adults with and without disabilities in the National Survey on drug use and health, 2015-2019

BACKGROUND

Little is known about the prevalence of injection drug use in people with disabilities (PWD) when compared by disability type and to other adults without disabilities.

OBJECTIVE OR HYPOTHESIS

The prevalence of past-year injection drug use will be higher in adults with a reported disability than adults without any reported disability.

METHODS

This study consisted of secondary analyses of data from the 2015-2019 National Survey of Drug Use and Health. The analytic sample comprised 214,505 US adults. Self-reported past-year injection drug use represented the outcome of interest. Disability status and socioeconomic characteristics were conceptualized as predictors, and sex and age were used as controls.

RESULTS

Past-year prevalence of self-reported injection drug use was 0.24 % (95 % CI, 0.22-0.27) in adults without a disability but 0.66 % (95 % CI, 0.59-0.73) in adults with a disability. All disability types examined were associated with increased odds of reporting past-year injection drug use, but the strongest association was observed for disability related to difficulty concentrating (AOR, 4.90; 95 % CI, 3.92-6.14). Adjusted odds of past-year methamphetamine injection were more than three times as high in adults with a disability, compared to those without a disability (AOR, 3.21; 95 % CI, 2.37-4.33) and more than two times as high in adults with a disability for cocaine injection (AOR, 2.77; 95 % CI, 1.84-4.15).

CONCLUSION

Disability status is associated with injection of various types of drugs, and a variety of disability types are associated with higher odds of injection drug use.

Metro/Nonmetro Migration as a Risk Factor for Opioid Use Disorder Among Older Medicare Beneficiaries: A Longitudinal Analysis of 2013-2018 Data

Opioid use disorder (OUD) among older adults (65+) has drawn researchers' attention. Nonetheless, whether migration between a metropolitan (metro) and nonmetropolitan (nonmetro) county shapes the risk of OUD remains underexplored. The drift hypothesis argues that individuals susceptible to a certain health condition tend to move, increasing the prevalence of the health condition in the destinations. By contrast, the environmental breeder hypothesis claims that migration alters the exposures to residential environment factors, which are associated with the occurrence of health conditions. Applying fixed-effects modeling to longitudinal data of older Medicare beneficiaries moving at least once between 2013 and 2018 (N = 6,227, person-year = 28,874), this study finds that older beneficiaries moving between metro and nonmetro counties demonstrated a higher risk of OUD than those who did not move. The positive association between migration and OUD risk is particularly strong for those moving from metro to nonmetro counties and the drift hypothesis receives stronger support.

Practitioner perspectives on working with older patients in opioid agonist treatment (OAT) in Norway: opportunities and challenges

BACKGROUND

Norway has a growing proportion of ageing opioid agonist treatment (OAT) patients, with 42% of the 8300 Norwegian OAT patients aged over 50 in 2022. This study aims to explore practitioners' views and experiences from treatment of ageing OAT patients.

METHODS

Data were collected as a series of semi-structured interviews with treatment staff (roles interviewed: doctor, psychologist, social worker, nurse, and learning disability nurse). Participants were recruited from three OAT outpatient clinics, one with an urban catchment area and two with a mix of urban and rural. The interviews incorporated questions on patients' somatic and mental health, strengths and weaknesses of the service for this group, and patients' quality of life.

RESULTS

Older patients were perceived to be more often stable in terms of substance use and housing situation, but also experiencing some key challenges in terms of cognitive impairment, loneliness and isolation, and comorbidities. Both the practitioner-patient relationship and healthcare interactions outside OAT had the potential to impact treatment quality positively or negatively depending on how they were managed.

CONCLUSIONS

Treating older patients in a way that respects and enhances their dignity is important. We argue that this requires better services for those whose functioning is impacted by cognitive impairment/dementia, an age-informed treatment model for this patient group, along with urgent work to improve municipal-level services given practitioners describe them as unacceptable in certain areas.

Longitudinal patterns of use of stimulants and opioids in the AIDS linked to the IntraVenous experience cohort, 2005-2019

BACKGROUND

Overdoses involving opioids and stimulants are on the rise, yet few studies have examined longitudinal trends in use of both substances. We sought to describe use and co-use of opioids and stimulants, 2005-2019, in the AIDS Linked to the Intravenous Experience (ALIVE) cohort - a community-based cohort of people with a history of injection drug use living in or near Baltimore, MD.

METHODS

We included 2083 ALIVE participants, who had at least two visits during the study period. Our outcome was based on self-reported use of opioids and stimulants in the prior 6 months. We estimated prevalence of 4 categories of use (neither stimulants nor opioids, only stimulants, only opioids, stimulants and opioids), using a non-parametric multi-state model, accounting for the competing event of death and weighting for informative loss to follow-up. All analyses were stratified by enrollment cohort, with the main analysis including participants who enrolled prior to 2015 and a sub-analysis including participants who enrolled 2015-2018.

RESULTS

In the main analysis, prevalence of using stimulants and opioids decreased from 38 % in 2005 to 12 % 2013 but stabilized from 2014 onwards (13-19 %). The prevalence of using only stimulants (7-11 %) and only opioids (5-10 %) was stable across time. Participants who reported using both were more likely to report homelessness, depression, and other substance use (e.g., marijuana and heavy alcohol use) than participants in the other use categories. On average, 65 % of visits with use of both were followed by a subsequent visit with use of both; of participants transitioning out of using both, 13% transitioned to using neither.

CONCLUSIONS

While use of stimulants and opioids declined in the cohort through 2013, a meaningful proportion of participants persistently used both. More research is needed to understand and develop strategies to mitigate harms associated with persistent use of both stimulants and opioids.

Older adult drug overdose: an application of latent class analysis to identify prevention opportunities

BACKGROUND

Older adult overdose death rates have increased significantly in recent years. However, research for prevention of drug overdose death specific to older adults is limited. Our objective is to identify profiles based on missed intervention points (touchpoints) to inform prevention of future older adult unintentional overdose deaths.

METHODS

We used latent class analysis methods to identify profiles of decedents aged 55 + years in the Illinois Statewide Unintentional Drug Overdose Reporting System. This system collects data on 92.6% of all unintentional overdose deaths in Illinois and includes data from death certificates, coroner/medical examiner, toxicology, and autopsy reports. Data include decedent demographics, circumstances leading up to and surrounding the fatal overdose and details regarding the overdose. Variables in the latent class analysis model included sex, race, alcohol test result, social isolation, recent emergency department (ED) visit, chronic pain, and pain treatment.

RESULTS

We identified three distinct decent profiles. Class 1 (13% of decedents) included female decedents who were in pain treatment, had physical health problems, and had greater likelihood of a recent ED visit before their death. Class 2 (35% of decedents) decedents were most likely to be socially connected (live with others, employed, had social or family relationships) but less likely to have recent healthcare visits. Class 3 (52% of decedents) decedents had higher social isolation (lived alone, unemployed, unpartnered), were mostly male, had fewer known physical health conditions, and more alcohol positivity at time of death. White decedents are clustered in class 1 while Black decedents are predominant in classes 2 and 3.

CONCLUSIONS

These profiles link to potential touchpoint opportunities for substance use disorder screening harm reduction and treatment. Class 1 members were most likely to be reachable in healthcare settings. However, most decedents were members of Classes 2 and 3 with less engagement in the healthcare system, suggesting a need for screening and intervention in different contexts. For Class 2, intervention touchpoints might include education and screening in work or social settings such as senior centers given the higher degree of social connectivity. For Class 3, the most isolated group, touchpoints may occur in the context of harm reduction outreach and social service delivery.

Use, Effects, and Diagnostic Challenges of Cocaine Use in "Baby Boomers" and Older Adults

Introduction

Substance use disorder (SUD) is frequently recognized in the literature as an epidemic in the United States, but less attention has been paid to the scale of the epidemic among people older than 60 years of age. As the cohort of individuals in this age group grows as a proportion of the population-the so-called aging of the population-the incidence of SUD in older adults will increase numerically as well. While most existing literature on SUD in the elderly has focused on alcohol, opioids, and prescription drugs, the number of users of stimulant drugs like cocaine and methamphetamine is also growing. We review literature on the use, effects, and diagnostic challenges of cocaine in adults in the so-called "Baby Boomer generation" (ages 59-77 in 2023), particularly those ≥65 years.

Methods

We performed a literature review of PubMed and Web of Science databases, supplemented by Google Scholar using combinations of "cocaine," "elderly," and "older adults." We searched the reference sections of particularly salient articles and utilized PubMed's and Google Scholars' "Cited By" and "Similar Articles" functions to find additional materials to include. We produced an annotated bibliography containing title and author information for each paper along with its abstract to select the papers to include; each author reviewed this bibliography to determine if articles were relevant, and if so, in which section(s) the material should be included. A total of 66 references have been included in this review.

Results

Both lifetime and current cocaine use appear to be more prevalent among members of the "Baby Boomer generation" than older cohorts. Though there has been limited research to inform clinical care for older adults who use cocaine, negative physical and psychosocial impacts have been noted in the literature. Cocaine use disorder may negatively affect the elderly more than younger users because of the increased vulnerability of their aging bodies to the physiological and cognitive effects of cocaine. Underdiagnosis of cocaine use in the elderly may be attributable to the assumption that any presenting symptoms are due to pre-existing medical conditions or that older adults are less likely to consume cocaine.

Conclusions

There is little information currently in the literature to help clinicians understand patterns and epidemiology of cocaine use, its effects on older adults and their common presentations after experiencing adverse events, and challenges of diagnosing and treating cocaine use in older adults. Additional research is needed to describe use and effects of cocaine on the elderly, particularly on age-related comorbid conditions and interactions with medications.

Health care and harm reduction provider perspectives on treating older adults who use non-medical opioids: a qualitative study set in Chicago

BACKGROUND

Opioid overdose death rates are increasing for adults aged 55 and older, with especially high rates in large urban areas. In parallel, admissions to treatment programs for older adults using illicit substances are increasing as well. Despite these trends, there is a lack of information about older adults who use non-medical opioids (NMO) and even less knowledge about their health and service encounters. Conducted in Chicago, Illinois, this qualitative study explores the perspectives of health care and harm reduction service providers who work with older adults using non-medical opioids.

METHODS

The study used snowball sampling to locate participants with expertise in working with older adults who use non-medical opioids. In total, we conducted 26 semi-structured interviews from September 2021-August 2022. We explored questions regarding participants' perceptions of older adult opioid use patterns, comorbidities, and involvement in harm reduction outreach and opioid use disorder treatment.

RESULTS

Many of the providers we interviewed consider older adults who use NMO as a distinct population that employ unique use behaviors with the intent to protect them from opioid overdose. However, these same unique behaviors may potentiate their risk for overdose in today's climate. Providers report initial encounters that are not care seeking for opioid use and primarily oriented around health conditions. Older adults who use non-medical opioids are seen as complex patients due to the need to diagnostically untangle symptoms of substance use from co-morbidities and conditions associated with aging. Treatment for this population is also viewed as complicated due to the interactions between aging, comorbidities, and substance use. Providers also noted that older adults who use NMO have use behaviors that make them less visible to outreach and treatment service providers, potentially putting them at increased risk for overdose and health conditions associated with opioid use.

CONCLUSIONS

Findings from this study are intended to inform future research on care provision for older adults who use non-medical opioids and may be especially applicable to large urban reas with histories of opioid use dating back to earlier drug epidemics of the 1970s, 1980s, and 1990s.

Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17

AIMS

To quantify the association between opioid agonist treatment (OAT) and overdose death by age group; test the hypothesis that across different age groups, opioid overdose mortality is lowest during OAT with buprenorphine compared with time out of treatment or OAT with methadone; and test associations between OAT and opioid overdose mortality in the presence of chronic circulatory, respiratory, liver and kidney diseases.

DESIGN

Retrospective observational cohort study using linked administrative data.

SETTING

New South Wales, Australia.

PARTICIPANTS

A total of 37 764 people prescribed OAT, 1 August 2002 and 31 December 2017.

MEASUREMENTS

OAT exposure, opioid overdose mortality and key confounders were measured using linked population data sets on OAT entry and exit, hospitalization, mental health care, incarceration and mortality. ICD-10 codes were used to define opioid overdose mortality and chronic disease groups of interest.

FINDINGS

Relative to time out of treatment, time in OAT was associated with a lower risk of opioid overdose death across all age groups and chronic diseases. Among people aged 50 years and older, there was weak evidence that buprenorphine may be associated with greater protection against opioid overdose death than methadone [generalized estimating equation (GEE) adjusted incident rate ratio (aIRR) = 0.47; 95% confidence interval (CI) = 0.21, 1.02; marginal structural models (MSM) aIRR = 0.49; 95% CI = 0.17, 1.41]. Buprenorphine was associated with greater protection against overdose death than methadone for clients with circulatory (MSM aIRR = 0.27; 95% CI = 0.11, 0.67) or respiratory (MSM aIRR = 0.26; 95% CI = 0.07, 0.94) diseases, but not liver (MSM aIRR = 0.59; 95% CI = 0.14, 2.43) or kidney (MSM aIRR = 1.16; 95% CI = 0.31, 4.36) diseases.

CONCLUSIONS

Opioid agonist treatment (OAT) appears to reduce mortality risk in people with opioid use disorder who are older or who have physical comorbidities. Opioid overdose mortality during OAT with buprenorphine appears to be lower and reduced in clients with circulatory and respiratory diseases compared with OAT with methadone.

The role of substance use in the lives of incarcerated older adults: A qualitative study

Background

The prevalence of drug abuse among older adults has grown over the last decade. Despite the expanding development of a body of research dedicated to studying this phenomenon, drug abuse by incarcerated older adults has been marginalized. Thus, the aim of the present study was to explore drug abuse patterns in the lives of incarcerated older adults.

Method

Semi-structured interviews were conducted with 28 incarcerated older adults, and an interpretive analysis was used to analyze the participants’ narratives.

Findings

Four themes emerged: (1) Growing up around drugs; (2) Prison onset; (3) Professionals, and (4) Lifelong substance abuse.

Conclusion

The study findings reveal a unique typology of drug-related themes in the lives of incarcerated older adults. This typology sheds light on the interplay between aging, drug use, and incarceration and the way these three socially marginalized positions may intersect.

"The Drug Sellers Were Better Organized than the Government": A Qualitative Study of Participants' Views of Drug Markets during COVID-19 and Other Big Events

"Big events", such as wars, economic crises, pandemics, or natural disasters, affect the risk environment in which people use drugs. While the impact of big events on injection risk behaviors and access to drug-treatment services is well documented, less is known about the effects of big events on drug markets. Based on self-reporting data on drug availability among people who use drugs (PWUD) in the aftermath of Hurricane Maria in Puerto Rico and during the COVID-19 lockdown in a Midwestern US state, this study aims to document the effects of big events on drug markets. Qualitative data on the effects of Hurricane Maria on drug markets are based on participants' self-reporting (N = 31). Data collection started after the hurricane and ended in 2020. Data on changes to the drug supply during the COVID-19 lockdown were collected based on semi-structured interviews with PWUD (N = 40) in a Midwestern US state. Findings show that while the drug markets might have initially been affected by big events, most effects were temporary. Drug availability, pricing, and quality might have suffered some initial fluctuations but stabilized as the drug markets absorbed the initial shocks caused by the hurricane and the lockdown measures. In preparation for increasingly more frequent and virulent pandemics and natural disasters, health infrastructures should be strengthened to prevent not only overdose episodes and deaths but also drug-related harms.

Substance use, injection risk behaviors, and fentanyl-related overdose risk among a sample of PWID post-Hurricane Maria

BACKGROUND

While natural disasters like hurricanes are increasingly common, their long-term effects on people who inject drugs are not well understood. Although brief in duration, natural disasters can radically transform risk environments, increasing substance use and drug-related harms.

METHODS

Based on a study of people who inject drugs (PWID) and injection risk behaviors in rural Puerto Rico, the present study uses data from two different phases of the parent study. Data for 110 participants were collected from December 2015 to January 2017, soon before Hurricane Maria landed in September 2017; the 2019 phase, in the aftermath of the hurricane, included a total of 103 participants. The present study's main analyses used data from 66 PWID who participated in both the pre-Maria and post-Maria interviews (66 individuals measured at two time points, for a total of 132 observations), using mixed-effects binomial logistic regression to examine recent overdose experiences pre- and post-Maria. A separate descriptive analysis included all 103 participants from the 2019 interview.

RESULTS

After Hurricane Maria, some declines in injection frequency were observed (the percentage of people reporting injecting monthly or less increased from 3.0% before Hurricane Maria to 22.7% after Hurricane Maria). However, fewer PWID reported using a new needle for most or all injections. In the pre-Maria interview, 10.6% of participants indicated they had experienced an overdose during the year of the interview and/or the calendar year prior, and this figure increased to 24.2% in the post-Maria interview. In the regression analysis, the odds of reporting an overdose during the interview year and/or calendar year prior were three times as high post-Maria, relative to pre-Maria (odds ratio 3.25, 95% confidence interval 1.06-9.97).

CONCLUSION

Substance use patterns, injection risk behaviors, and overdose episodes and deaths differed after Hurricane Maria, relative to before the hurricane, yet it is unclear to what extent these changes also reflect the simultaneous arrival of fentanyl. In preparation for future natural disasters, it is imperative to strengthen the health infrastructure by enhancing access and curbing barriers to syringe services programs and medications for opioid use disorder, particularly in rural or underserved locations.